We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Microarray Platform Demonstrates High Performance and Cost Effectiveness

By Labmedica staff writers
Posted on 01 Apr 2008
An objective comparison of tiling microarray array platforms using engineered DNA targets demonstrated their high performance and cost effectiveness.

The study organized by members of the Encyclopedia of DNA Elements consortium (ENCODE; Bethesda, MD, USA) at the University of North Carolina at Chapel Hill (Chapel Hill, NC, USA), the Dana-Farber Cancer Institute (Boston, MA, USA), and Stanford University (Stanford, CA, USA) evaluated DNA microarrays from Agilent (Santa Clara, CA, USA), Affymetrix (Santa Clara, CA, USA), and Nimblegen (Madison, WI, USA), which were used in seven independent laboratories.

The composition of the spike-in DNA in this study was engineered to mimic chromatin immunoprecipitation (ChIP) or copy-number amplification experiments across a wide dynamic range. More...
To ensure a fair evaluation, the composition was not disclosed to participants. This made it possible to quantitatively evaluate each platform's sensitivity and specificity of detecting and quantifying a predefined standard without bias.

Platforms were compared using their highest possible tiling density. In evaluating results from comparable algorithms, Agilent consistently achieved the highest or equivalent scores, but did so with fewer probes, half as many replicates, and less sample DNA than either of the other platforms.

The study found that longer oligonucleotide (60-nt) microarrays, such as Agilent's, were more sensitive at detecting very low enrichment or copy number. Additionally, Agilent demonstrated the highest levels of sensitivity and specificity per probe, in some cases by orders of magnitude, over a range of simulated tiling densities.

"Agilent proved to be the most cost-effective of the long-oligo platforms over a wide range of tiling densities relevant to not only ChIP-on-chip assays but also to aCGH [array comparative genomic hybridization],” said Yvonne Linney, Ph.D., VP and general manager of Agilent's Genomics business. "The cost advantage is the result of our superior probe performance, which is due to the high quality of our SurePrint in situ oligonucleotide synthesis combined with our robust probe design algorithms. The bottom line is that the increased performance of Agilent's probes makes it possible to get more data with fewer features.”

The study was published in the journal Genome Research in March 2008.


Related Links:
Encyclopedia of DNA Elements consortium
University of North Carolina
Dana-Farber Cancer Institute

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Automated Clinical Chemistry Analyzer
Envoy 500+
Immunofluorescence Analyzer
IFA System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers from the Department of Chemistry at Aarhus University have developed and tested a new technology that can identify and measure the concentration of pharmaceuticals in under 10 minutes. Today, this process takes up to an hour. That is critical waiting time for patients suffering from a stroke. (Image Credit: Aarhus University)

Point-of-Care Blood Test Could Speed Treatment Decisions in Acute Stroke

Minutes can shape treatment decisions in emergency stroke care, particularly when physicians need to know whether a patient is taking anticoagulants before administering clot-dissolving therapy.... Read more

Microbiology

view channel
Image: The clearance also broadens QIAstat-Dx\'s infectious disease testing menu in the U.S., which already includes panels for respiratory and gastrointestinal infections, as well as meningitis and encephalitis (Photo courtesy of Qiagen)

One-Hour Molecular Panel Expands Bloodstream Infection Testing for Gram-Negative Pathogens

Bloodstream infections can progress rapidly and lead to sepsis, organ failure, and death. In the United States, about 1.7 million adults develop sepsis each year, and at least 350,000 die during hospitalization... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.